Join Growin Stock Community!

Icu medical, inc.ICUI.US Overview

US StockHealthcare
(No presentation for ICUI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ICUI AI Insights

ICUI Overall Performance

ICUI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ICUI Recent Performance

-3.48%

Icu medical, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ICUI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ICUI Key Information

ICUI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ICUI Profile

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.

Price of ICUI

ICUI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ICUI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.03
PE Ratio (TTM)
-
Forward PE
17.23
PS Ratio (TTM)
1.67
PB Ratio
1.75
Price-to-FCF
39.92
METRIC
VALUE
vs. INDUSTRY
Gross Margin
36.84%
Net Margin
0.03%
Revenue Growth (YoY)
-6.33%
Profit Growth (YoY)
-0.33%
3-Year Revenue Growth
-2.20%
3-Year Profit Growth
5.08%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
0.03
PE Ratio (TTM)
-
Forward PE
17.23
PS Ratio (TTM)
1.67
PB Ratio
1.75
Price-to-FCF
39.92
Gross Margin
36.84%
Net Margin
0.03%
Revenue Growth (YoY)
-6.33%
Profit Growth (YoY)
-0.33%
3-Year Revenue Growth
-2.20%
3-Year Profit Growth
5.08%

  • When is ICUI's latest earnings report released?

    The most recent financial report for Icu medical, inc. (ICUI) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ICUI's short-term business performance and financial health. For the latest updates on ICUI's earnings releases, visit this page regularly.

  • Where does ICUI fall in the P/E River chart?

    According to historical valuation range analysis, Icu medical, inc. (ICUI)'s current price-to-earnings (P/E) ratio is 5,050.71, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ICUI?

    According to the latest financial report, Icu medical, inc. (ICUI) reported an Operating Profit of 5.64M with an Operating Margin of 1.04% this period, representing a decline of 84.47% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ICUI's revenue growth?

    In the latest financial report, Icu medical, inc. (ICUI) announced revenue of 540.7M, with a Year-Over-Year growth rate of -14.15%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ICUI have?

    As of the end of the reporting period, Icu medical, inc. (ICUI) had total debt of 1.28B, with a debt ratio of 0.32. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ICUI have?

    At the end of the period, Icu medical, inc. (ICUI) held Total Cash and Cash Equivalents of 307.96M, accounting for 0.08 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ICUI go with three margins increasing?

    In the latest report, Icu medical, inc. (ICUI) did not achieve the “three margins increasing” benchmark, with a gross margin of 37.5%%, operating margin of 1.04%%, and net margin of -2.9%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ICUI's profit trajectory and future growth potential.

  • Is ICUI's EPS continuing to grow?

    According to the past four quarterly reports, Icu medical, inc. (ICUI)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.64. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ICUI?

    Icu medical, inc. (ICUI)'s Free Cash Flow (FCF) for the period is 42.21M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 209.31% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ICUI?

    The latest valuation data shows Icu medical, inc. (ICUI) has a Price-To-Earnings (PE) ratio of 5,050.71 and a Price/Earnings-To-Growth (PEG) ratio of -0.16. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.